The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Society for Maternal-Fetal Medicine Consult Series #69: Hepatitis B in Pregnancy: Updated Guidelines
Am J Obstet Gynecol. 2023 Dec 21:S0002-9378(23)02173-7. doi: 10.1016/j.ajog.2023.12.023.Online ahead of print.
More than 290 million people worldwide, and almost 2 million people in the United States, are infected with hepatitis B virus (HBV), a vaccine-preventable communicable disease. The estimated prevalence of chronic hepatitis B infection in pregnancy is estimated to be 0.7-0.9% in the United States, with>25,000 infants born annually at risk for chronic infection due to perinatal or vertical transmission. Given the burden of disease associated with chronic hepatitis B infection, recent national guidance has expanded indications for screening for hepatitis B infection and immunity and expanded indications for vaccination. The purpose of this document is to aid clinicians caring for pregnant patients in screening for hepatitis B infection and immunity status, discuss the perinatal risks of hepatitis B infection in pregnancy, determine whether treatment is indicated for maternal or perinatal indications, and recommend hepatitis B vaccination among susceptible patients. The following are Society for Maternal-Fetal Medicine recommendations: (1) we recommend triple panel testing (hepatitis B surface antigen screening, antibody to HBsAg, and total antibody to hepatitis B core antigen) at the initial prenatal visit if not previously documented or known to have been performed (GRADE 1C); (2) we recommend universal hepatitis B surface antigen screening alone at the initial prenatal care visit for all pregnancies where there has been a previously documented negative triple panel test (GRADE 1B); (3) we recommend that individuals with unknown hepatitis B surface antigen screening status should be tested on any presentation for care in pregnancy. We also recommend that those with clinical hepatitis, or those with risk factors for acute hepatitis B infection should be tested at the time of admission to a birthing facility when delivery is anticipated (GRADE 1B); (4) we do not recommend altering routine intrapartum care in individuals chronically infected with hepatitis B. Administration of neonatal immunoprophylaxis is standard of care in these situations (GRADE 1B); (5) we do not recommend cesarean delivery for the sole indication of reducing perinatal hepatitis B virus transmission (GRADE 1B); (6) we recommend that individuals with hepatitis B infection can breastfeed as long as the infant receives immunoprophylaxis at birth (GRADE 1C); (7) we suggest that hepatitis B virus-infected individuals who desire invasive testing may have the procedure performed after an informed discussion on risks and benefits in the context of shared decision-making and in the context of how testing will affect clinical care (GRADE 2C); (8) in individuals with hepatitis viral loads >200,000 IU/mL (>5.3 log 10 IU/mL), we recommend antiretroviral therapy with tenofovir (tenofovir alafenamide at 25 mg daily or tenofovir disoproxil fumarate at 300 mg daily) in the third trimester (initiated at 28-32 weeks of gestation) as an adjunctive strategy to immunoprophylaxis to reduce vertical transmission (GRADE 1B); (9) we recommend administering hepatitis B vaccine and hepatitis B immunoglobin within 12 hours of birth to all newborns of hepatitis B surface antigen-positive pregnant patients or those with unknown or undocumented hepatitis B surface antigen status, regardless of whether antiviral therapy has been given during the pregnancy to the pregnant patient (GRADE 1B); (10) we recommend hepatitis B vaccination in pregnancy for all individuals without serologic evidence of immunity or documented history of vaccination (GRADE 1C).